对抗癌症药物相关的间歇性肺部疾病的FDA不良事件报告系统的药物监测研究和遗传标预测分析
Shun Li1, Weijian Miao1, Qimeng Tao1
1Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233000, Anhui, China.
Naunyn-Schmiedeberg's archives of pharmacology
|January 29, 2026
概括
抗癌药物诱导的间歇性肺病 (ILD) 风险与CD40有关,特别是在gemcitabine. 这项研究确定了参与ILD发展的特定免疫细胞和代谢物,提供了新的预防和治疗策略.
科学领域:
- 在瘤学瘤学.
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 与抗癌药物相关的间歇性肺病 (ILD) 是一个显著的不良事件.
- 识别高风险的抗癌药物和了解它们的致病机制对于患者管理至关重要.
研究的目的:
- 在固体瘤患者中确定与ILD强烈相关的抗癌药物.
- 阐明与抗癌药物相关的ILD的致病机制,重点关注分子标和介导因素.
主要方法:
- 利用21年的美国FDA不良事件报告系统 (FAERS) 数据进行不成比例分析和后勤回归.
- 采用网络药理学来识别抗癌药物和ILD之间的重叠目标.
- 应用孟德尔随机化 (MR) 和分子对接来评估因果关系和药物标结合.
- 进行中介MR分析,以调查免疫细胞和代谢物在CD40中介ILD中的作用.
主要成果:
- 确定了21种抗癌药物作为独立的ILD风险因素,大多数药物表现为早期失效 (3个月内).
- 确定CD40作为一个关键的致病性标,CD40的高表达因果上会增加ILD风险.
- 通过分子对接证实了gemcitabine和CD40之间的稳定结合.
- 透露的CD40通过特定的调节性T细胞 (Tregs) 和代谢物 (例如,SAH与5-甲基尤里丁的比率) 影响ILD.
结论:
- CD40是与抗癌药物相关的ILD的关键贡献者,特别是在gemcitabine.
- CD40通过对特定Tregs和代谢物的失调来发挥其致病作用.
- 这些发现为疾病机制提供了新的见解,并确定了ILD预防和治疗的潜在治疗点.
相关概念视频
01:26FDA Approved Drugs: Changes to Approved Drugs
268
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
268
01:19Pharmacovigilance
1.7K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.7K
01:26Targets for Drug Action: Overview
10.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.2K
01:47Lung Capacity
56.3K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.3K
02:27Predicting Molecular Geometry
45.8K
VSEPR Theory for Determination of Electron Pair Geometries
45.8K
00:49What is Genetic Engineering?
80.1K
Overview
80.1K